CD274 and neoplasm: In clinical trials targeting PD-1 or PD-L1 in TNBC patients, those who expressed higher levels of PD-L1 in the tumor microenvironment experienced better responses; for this reason, evaluating the combination of CTX with PD-L1 blockade seemed like a logical pursuit.